Skip to main content
SpringerLink
Log in
Book cover

Atlas of Surgical Therapy for Migraine and Tension-Type Headache pp 45–50Cite as

Botulinum Neurotoxin: Basic Facts, Physiology and Pharmacology

  • Chapter
  • First Online:

Abstract

Globally recognised botulinum neurotoxin is known primarily for its aesthetic effects. It seems to attract a negative media slant disproportionate to its wealth of clinically documented attributes in fields as disparate as paediatrics, urology, ophthalmology and, most recently, neurology for its treatment of migraine. This chapter introduces some of its important facts, fundaments of physiology and basic pharmacology.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70.

    Article  CAS  PubMed  Google Scholar 

  2. van Ermengen EP. Über einen neuen anaëroben Bacillus and seine Beziehungen zum Botulismus. Z Hyg Infektionskrankh. 1897;26:1–56.

    Google Scholar 

  3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–9.

    Article  CAS  PubMed  Google Scholar 

  4. Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin A injection as a treatment for blepharospasm. Arch Opththalmol. 1985;103:347–50.

    Article  CAS  Google Scholar 

  5. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.

    Article  CAS  PubMed  Google Scholar 

  6. https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-report-2018.pdf. Accessed 11 June 2019.

  7. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 1980;44:419–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015;166:290–302.

    Article  PubMed  Google Scholar 

  10. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898–902.

    Article  CAS  PubMed  Google Scholar 

  11. Rawlings ND, Barrett AJ. Homologues of insulinase, a new superfamily of metalloendopeptidases. Biochem J. 1991;275:389–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miyata K, Yoneyama T, Suzuki T, et al. Expression and stability of the nontoxic component of the botulinum toxin complex. Biochem Biophys Res Commun. 2009;384:126–30.

    Article  CAS  PubMed  Google Scholar 

  13. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7:693–9.

    Article  CAS  PubMed  Google Scholar 

  14. Setlow P. I will survive: DNA protection in bacterial spores. Trends Microbiol. 2007;15:172–80.

    Article  CAS  PubMed  Google Scholar 

  15. Pickett J, Berg B, Chaplin E, Brunstetter-Shafer MA. Syndrome of botulism in infancy: clinical and electrophysiological study. N Engl J Med. 1976;295:770–2.

    Article  CAS  PubMed  Google Scholar 

  16. Cartee TV, Monheit GD. An overview of botulinum toxins: past, present, and future. Clin Plast Surg. 2011;38:409–26.

    Article  PubMed  Google Scholar 

  17. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 1984;307:457–60.

    Article  CAS  PubMed  Google Scholar 

  19. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol. 2003;10:13–8.

    Article  CAS  PubMed  Google Scholar 

  20. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–66.

    Article  CAS  PubMed  Google Scholar 

  21. Lagow RD, Bao H, Cohen EN, et al. Modification of a hydrophobic layer by a point mutation in syntaxin 1A regulates the rate of synaptic vesicle fusion. PLoS Biol. 2007;5:e72.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Barr JR, Moura H, Boyer AE, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005;11:1578–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Montecucco C, Schiavo G, Pantano S. SNARE complexes and neuroexocytosis: how many, how close? Trends Biochem Sci. 2005;30:367–72.

    Article  CAS  PubMed  Google Scholar 

  24. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–80.

    Article  CAS  PubMed  Google Scholar 

  25. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett. 1997;224:91–4.

    Article  CAS  PubMed  Google Scholar 

  26. Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333–68.

    Article  PubMed  Google Scholar 

  27. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–90.

    Article  CAS  PubMed  Google Scholar 

  28. Allergan, Inc. Irvine, CA, USA Botox® Cosmetic; package insert.

    Google Scholar 

  29. Ipsen Biopharm Ltd., Wrexham, UK; package insert.

    Google Scholar 

  30. Merz Pharmaceuticals GmbH, Frankfurt, Germany; package insert.

    Google Scholar 

  31. Lowe NJ. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg. 1998;24:1216–8.

    CAS  PubMed  Google Scholar 

  32. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121:413e–22e.

    Article  PubMed  CAS  Google Scholar 

  33. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology. 1986;36:545–7.

    Article  CAS  PubMed  Google Scholar 

  34. Osako M, Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol. 1991;36:28–46.

    Article  CAS  PubMed  Google Scholar 

  35. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–5.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Angaut-Petit D, Molgó J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience. 1990;37:799–808.

    Article  CAS  PubMed  Google Scholar 

  37. Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112:171S–3S.

    Article  PubMed  Google Scholar 

  38. Burstein R, Zhang X, Levy D, Aoki K, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853–69.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333–5.

    Article  CAS  PubMed  Google Scholar 

  40. Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc. 1989;87:174–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Carruthers A. Problems with toxins. Body Lang. 2010;35:43–4.

    Google Scholar 

  42. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–15.

    Article  PubMed  Google Scholar 

  43. Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis. J Forensic Sci. 2005;50:169–72.

    PubMed  Google Scholar 

  44. Bai L, Peng X, Liu Y, et al. Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT). Medicine (Baltimore). 2018;97:e10659.

    Article  CAS  Google Scholar 

  45. Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord. 1995;10:574–9.

    Article  CAS  PubMed  Google Scholar 

  46. Tyler HR. Botulinus toxin: effect on the central nervous system of man. Science. 1963;139:847–8.

    Article  CAS  PubMed  Google Scholar 

  47. Marinelli S, Vacca V, Ricordy R, et al. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012;7:e47977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Matak I, Lacković Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119–120:39–59.

    Article  PubMed  CAS  Google Scholar 

  49. Söylev MF, Koçak N, Kuvaki B, Ozkan SB, Kir E. Anaesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002;216:355–8.

    Article  PubMed  CAS  Google Scholar 

  50. Eppley BL. Easing Botox administration with EMLA cream. Aesthet Surg J. 2004;24:79–81.

    Article  PubMed  Google Scholar 

  51. Sami MS, Soparka CNS, Patrinely JR, Hollier LM, Hollier LH. Efficacy of Botulinum toxin type A after topical anaesthesia. Ophthal Plast Reconstr Surg. 2006;22:448–5.

    Article  PubMed  Google Scholar 

  52. Brin MF, Boodhoo T, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61:961–70.

    Article  CAS  PubMed  Google Scholar 

  53. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety and antibody frequency. J Neurol. 1999;246:265–74.

    Article  CAS  PubMed  Google Scholar 

  55. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord. 2010;25:2211–8.

    Article  PubMed  Google Scholar 

  56. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32:213–8.

    Article  CAS  PubMed  Google Scholar 

  57. Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg. 2007;33:S105–10.

    Article  CAS  PubMed  Google Scholar 

  58. Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519–22.

    PubMed  Google Scholar 

  59. Dressler D, Rothwell JC. Electromyographic quantification of the paralyzing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol. 2000;43:13–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

Conflict of Interest: The author has no conflict of interest to declare.

Author information

Authors and Affiliations

  1. London Welbeck Hospital, London, UK

    M. G. Berry

Authors
  1. M. G. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. G. Berry .

Editor information

Editors and Affiliations

  1. Department of Medicine and Surgery, University of Parma, Parma, Italy

    Edoardo Raposio

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Berry, M.G. (2020). Botulinum Neurotoxin: Basic Facts, Physiology and Pharmacology. In: Raposio, E. (eds) Atlas of Surgical Therapy for Migraine and Tension-Type Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-29505-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-29505-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-29504-2

  • Online ISBN: 978-3-030-29505-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation